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The Parietal Epithelial Cell: A Key Player in the Pathogenesis
of Focal Segmental Glomerulosclerosis in Thy-1.1
Transgenic Mice
BART SMEETS,* NATHALIE A.J.M. TE LOEKE,* HENRY B.P.M. DIJKMAN,*
MARK L.M. STEENBERGEN,* JOOST F.M. LENSEN‡, MARK P.V. BEGIENEMAN,*
TOIN H. VAN KUPPEVELT,‡ JACK F.M. WETZELS,† and ERIC J. STEENBERGEN*
Departments of *Pathology, †Nephrology, and ‡Biochemistry, University Medical Center Nijmegen, Nijmegen,
the Netherlands.
Abstract. Focal segmental glomerulosclerosis (FSGS) is a hall-
mark of progressive renal disease. Podocyte injury and loss
have been proposed as the critical events that lead to FSGS. In
the present study, the authors have examined the development
of FSGS in Thy-1.1 transgenic (tg) mice, with emphasis on the
podocyte and parietal epithelial cell (PEC). Thy-1.1 tg mice
express the Thy-1.1 antigen on podocytes. Injection of anti-
Thy-1.1 mAb induces an acute albuminuria and development
of FSGS lesions that resemble human collapsing FSGS. The
authors studied FSGS lesions at days 1, 3, 6, 7, 10, 14, and 21,
in relation to changes in the expression of specific markers for
normal podocytes (WT-1, synaptopodin, ASD33, and the Thy-
1.1 antigen), for mouse PEC (CD10), for activated podocytes
(desmin), for macrophages (CD68), and for proliferation (Ki-
67). The composition of the extracellular matrix (ECM) that
forms tuft adhesions or scars was studied using mAb against
collagen IV 2 and 4 chains and antibodies directed against
different heparan sulfate species. The first change observed
was severe PEC injury at day 1, which increased in time, and
resulted in denuded segments of Bowman’s capsule at days 6
and 7. Podocytes showed foot process effacement and mi-
crovillous transformation. There was no evidence of podocyte
loss or denudation of the GBM. Podocytes became hypertro-
phic at day 3, with decreased expression of ASD33 and syn-
aptopodin and normal expression of WT-1 and Thy-1.1. Podo-
cyte bridges were formed by attachment of hypertrophic
podocytes to PEC and podocyte apposition against denuded
segments of Bowman’s capsule. At day 6, there was a marked
proliferation of epithelial cells in Bowman’s space. These
proliferating cells were negative for desmin and all podocyte
markers, but stained for CD10, and thus appeared to be PEC.
The staining properties of the early adhesions were identical to
that of Bowman’s capsule, suggesting that the ECM in the
adhesions was produced by PEC. In conclusion, the authors
propose the following sequence of events leading to FSGS
lesions in the Thy1.1 tg mice: (1) PEC damage and denudation
of Bowman’s capsule segments; (2) podocyte hypertrophy and
bridging; and (3) PEC proliferation with ECM production.
Focal segmental glomerulosclerosis (FSGS), a hallmark of
progressive renal disease, is one of the most common patterns
of glomerular injury encountered in human renal biopsies (1).
In its classical form, FSGS is characterized by mesangial
sclerosis, obliteration of glomerular capillaries, formation of
adhesions between the glomerular tuft and Bowman’s capsule,
podocyte hypertrophy, hyalinosis, and intracapillary foam
cells. More recently, various morphologic variants have been
described (2). Notably, FSGS is merely a descriptive diagnosis
and not a disease entity. Clinically, presentation of the patients
varies widely (3).
FSGS was long considered to be the consequence of mes-
angial overload leading to mesangial cell proliferation, mesan-
gial cell injury, and increased production of extracellular ma-
trix (ECM) (4–7). More recently, focus has turned on the
visceral epithelial cell, the so-called podocyte. Seminal studies
of Kriz et al. (8–17) in various rat models of FSGS have
proposed the following sequence of events that ultimately lead
to FSGS: (1) podocyte injury resulting in podocyte loss with
denudation of the GBM; (2) adherence of the parietal epithelial
cell (PEC) to the naked GBM; (3) formation of an adhesion of
the GBM to Bowman’s capsule; (4) misdirected filtration of
proteins to the periglomerular and peritubular space. However,
the studies by Kriz et al. were performed in animal models in
which a common feature was glomerular hypertension with
capillary ballooning and the development of hypocellular
FSGS lesions, which resemble lesions observed in human
secondary FSGS. Their findings may therefore not apply to
FSGS in general. Recently, we have proposed the Thy-1.1
transgenic (tg) mice as a mouse model to study proteinuria and
FSGS (18). Thy-1.1 tg mice carry a mouse-human chimeric
transgene that causes ectopic expression of the mouse Thy-1.1
antigen on podocytes. Injection of mAb directed against the
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Thy-1.1 antigen induces an acute albuminuria within 10 min
and a dose-dependent development of FSGS within 3 wk (19).
FSGS lesions in this mouse model bear resemblance to the
collapsing variant of human FSGS.
In the present study, we have examined the histopathologic
changes that occur in the early stages of FSGS development.
We particularly focused on the podocytes and PEC. Our results
indicate that PEC play the principal role in the formation of
FSGS lesions in this mouse model.
Materials and Methods
Animals
Heterozygous Thy-1.1 tg mice were kindly provided by Dr. D.J.
Evans (T6, T-construct mice (20)). These mice were generated by
injecting a hybrid human-mouse Thy-1.1 gene into pronuclei of zy-
gotes of Thy-1.2 CBA  C57BL/10 mice. These mice express the
Thy-1.1 gene abnormally in podocytes, resulting in the presence of the
Thy-1.1 antigen on the podocytes. All mice were bred in our animal
facility. Breading pairs consisted of a heterozygous (/) tg mouse
and its non-tg (/) counterpart. The presence of the tg was exam-
ined by PCR on genomic DNA from the tail, with a forward primer:
5'-CGCCTGAGTCCTGATCTCC-3' and a reverse primer: 5'-AAC-
CTGCATCTTCACTGGGT-3'. The presence of the tg resulted in a
specific 834-bp amplicon. As a positive control for the presence of
amplifiable genomic DNA, a primerset for aminopeptidase A (APA;
EC 3.4.11.7), consisting of the forward primer: 5'-ACACAAC-
CCCAGCTCCTTCC-3' and reverse primer 5'-TCTTCTGCAGCCT-
GGATCAC-3', was used. The amplification of the APA gene with
these primers resulted in a 367-bp amplicon.
Anti-Thy-1.1 mAb
For in vivo experiments, a mouse anti-mouse Thy-1.1 mAb
(19XE5: subclass IgG3) was used. 19XE5 was generated in vitro, by
hollow fiber culture, purified by protein-A column affinity chroma-
tography and concentrated (Nematology Department, Agriculture
University Wageningen, The Netherlands). The mAb was decomple-
mented at 56°C for 45 min and sterilized by passage through a sterile
0.2-m filter, and stored at 80°C.
Animal Experiments
Five-week-old Thy-1.1 tg mice received an intravenous injection
with 1 mg anti-Thy-1.1 mAb (19XE5) in 0.1 ml 0.9% saline solution.
Transgenic mice injected with 0.1 ml 0.9% saline solution alone were
used as controls. To evaluate the FSGS development, kidney samples
were collected at days 1, 3, 6, 7, 10, 14, and 21 after anti-Thy-1.1 mAb
injection.
Light Microscopy and Transmission
Electron Microscopy
For light microscopy, kidney fragments were fixed in Bouin solu-
tion, dehydrated, and embedded in paraplast (Amstelstad, Amsterdam
The Netherlands). Four-micrometer sections were stained with peri-
odic acid-Schiff, and 2-m sections with silver methenamine (21). At
least 60 glomeruli per mouse were evaluated. We determined the
percentage of glomeruli with a FSGS lesion (FGS score). Only lesions
with an adhesion (matrix continuity between the tuft and Bowman’s
capsule in the silver stain) were counted. The number of nuclei in
Bowman’s space was determined (expressed as nuclei/glomerular
cross section) and served as an objective measure for hyperplasia of
glomerular epithelial cells.
For electron microscopy, we used immersion and perfusion fixed
kidneys. For immersion fixation, small fragments of cortex were fixed
in 2.5% glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer,
pH 7.4, overnight at 4°C and washed in the same buffer. To obtain
perfusion fixed kidneys, anti-Thy-1.1–injected mice were perfused
retrogradely via the aorta. The animals were flushed for 30 s with a
buffered saline solution and perfused with a 2.5% glutaraldehyde
dissolved in 0.1 M sodium cacodylate buffer, pH 7.4, for 10 min.
Perfusion was performed at a pressure of 120 mmHg. Small fragments
of cortex were further fixed by immersion in the same fixative
overnight at 4°C and washed in 0.1 M sodium cacodylate buffer, pH
7.4. The tissue fragments were postfixed in Palade-buffered 2% OsO4
for 1 h, dehydrated, and embedded in Epon812, Luft procedure
(Merck, Darmstadt, Germany). Ultrathin serial sections with 2-m
intervals were contrasted with 4% uranyl acetate for 45 min and
subsequently with lead citrate for 5 min at room temperature. Sections
were examined in a Jeol 1200 EX2 electron microscope (JEOL,
Tokyo, Japan).
Immunohistochemistry
Immunohistochemical staining was performed on kidneys, fixed in
4% buffered formaldehyde for 24 h and embedded in paraffin. Four-
micrometer sections were incubated with rat rabbit anti-mouse Ki-67
(Dianova Immundiagnostic, Hamburg, Germany), goat anti-CD10,
and rabbit anti-WT-1 (Santa Cruz Biotechnology, Santa Cruz, CA).
As secondary antibodies we used, a biotinylated goat anti-rabbit
antibody for Ki-67 and WT-1, and a horse anti-goat for CD10 (Vector
laboratories Inc., Burlingame, CA). Detection was carried out with
vectastain ABC kit (Vector Laboratories, Burlingame, CA) with the
use of peroxidase as label and diaminobenzidine as substrate. Quan-
tification of the WT-1 and Ki-67–positive cells was performed with
the Zeiss KS 400 image analysis system (Carl Zeiss b.v., Weesp, The
Netherlands). Images were acquired using AxioPlan2 imaging micro-
scope and AxioCam MRc digital ccd camera (Carl Zeiss b.v., Weesp,
The Netherlands). The outline of individual glomeruli and segments
of interstitium were interactively drawn using a graphic tablet. Posi-
tive nuclei in the selected areas were interactively marked. A custom-
ized macro under KS400 software (KS400 3.0) determined the area
(mm2) of the selected segments, and the number of positive nuclei
within this area. Approximately 30 glomeruli per mouse were counted
in one cross-section. For staining of CD68 and desmin, we used 2-m
acetone fixed cryosections. The sections were incubated with rat
anti-mouse CD68 (clone FA-11; Serotec, Oxford, UK), and rabbit
anti-desmin (22). As secondary antibodies we used biotinylated rabbit
anti-rat for CD68 and biotinylated goat anti-rabbit antibody for
desmin (Vector laboratories Inc., Burlingame, CA). Detection was
carried out with vectastain ABC kit for alkaline phophatase detection
(Vector Laboratories, Burlingame, CA).
Immunofluorescence Microscopy
Kidney fragments were snap-frozen in liquid nitrogen, and 2-m
acetone fixed serial cryostat sections were used. Thy-1.1 was detected
using a rat polyclonal anti-Thy-1 antibody (59AD2.2; IgG2a, (23)).
As secondary antibody, we used a FITC-labeled sheep anti-rat anti-
body (Serotec, Oxford, UK). A double-immunolabeling technique
was performed to determine the co-localization of Thy-1.1 and Ki-67
and of Thy1.1 and desmin. Thy-1.1 was stained as described above.
After washing with PBS, the sections were incubated with rabbit
anti-mouse Ki-67 (Dianova Immundiganostic, Hamburg Germany) or
with rabbit anti-desmin (22) and detected with a goat anti-rabbit Alexa
568 antibody (Molecular Probes Inc, Leiden, The Netherlands). Syn-
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aptopodin was detected using an anti-synaptopodin mAb (Progen
Biotechnik, Heidelberg, Germany), followed by FITC-labeled sheep
anti-mouse IgG1 (Nordic Immunologicals, Tilburg, The Netherlands).
For detection of the podocyte, we also have used ASD33, a rat
monoclonal antibody, generated in our laboratory, which only reacts
with the podocyte cell membrane (24). The identity of the antigen is
unknown. For the detection of ASD33, we have used FITC-labeled
rabbit anti-rat antibody (Dako A/S, Glostrup, Denmark). Type IV
collagen 2 and 4 chains were detected with rat monoclonal anti-
bodies directed against human collagen (IV) 2 (H22) and human
collagen (IV) 4 (H43), a gift from Dr. Yoshikazu Sado (Shigei
Medical Research Institute, Okayama, Japan). Detection was done
using goat anti-rat Alexa 488/568 antibodies (Molecular Probes Inc,
Leiden, The Netherlands). Nuclei were stained with TO-PRO-3 (Mo-
lecular Probes Inc, Leiden, The Netherlands), a monomeric cyanine
nucleic acid stain. Different heparan sulfate species were detected
with various single chain antibodies, HS4C3 (25), HS4E4, and
EV3C3 (26). The single chain antibodies were detected with a Cy3-
labeled rabbit antibody directed against the VSV-g epitope tag (Sig-
ma-Aldrich, Zwijndrecht, The Netherlands). The sections were exam-
ined with a confocal laser-scanning microscope (CLSM) (Leica
lasertechnik GmbH, Heidelberg, Germany).
Statistical Analyses
For multiple comparisons, ANOVA was used and post hoc analy-
ses were done with Tukey test. P  0.05 was considered significant.
All values are expressed as means  SEM.
Results
Histopathology of the Kidney
Thy-1.1 tg mice that received a single injection of 1 mg
anti-Thy-1.1 mAb developed FSGS lesions within 3 wk. The
histopathology was examined by light microscopy at days 1, 3,
6, 7, 10, and 21 (Figure 1). At day 1, we observed enlarged
Bowman’s space due to collapse of the glomerular tuft, con-
sistent with ischemia. No enlarged podocytes (hypertrophy)
were observed. In contrast, PEC showed vacuolization and
detachment. In tubular lumens we observed many hyaline
appearing protein casts. Proximal tubular epithelial cells
showed damage similar to PEC (Figure 1A). At day 3, glo-
meruli were not ischemic anymore, and the number of tubular
protein casts had decreased. There was segmental hypertrophy
of glomerular epithelial cells (Figure 1B). At days 6 and 7, the
first FSGS lesions with tuft adhesions to Bowman’s capsule
were observed. Affected glomeruli showed segmental collapse
of the capillary tuft and a marked increase of epithelial cells in
Bowman’s space (Figure 1, C and D). It was shown that there
was a significant overall increase of the number of nuclei in
bowman’s space at day 7 (Table 1). Adhesions (continuity of
ECM between the capillary tuft and Bowman’s capsule) were
formed by thin strands of ECM that were located in between
the epithelial cells in Bowman’s space. Sporadically (not quan-
tified) we observed endocapillary foam cells, an endocapillary
neutrophil or mononuclear cell, mild mesangial hypercellular-
ity, and mild hyalinosis (Figure 1F). From a histologic point of
view, the FSGS lesions closely resembled the collapsing vari-
ant of human FSGS (27). The percentage of glomeruli with
FSGS lesions was scored at days 1, 3, 6, 7, 10, and 21 by light
microscopy (Figure 1G). FSGS lesions, with tuft adhesions to
Bowman’s capsule, could be observed in 11  1% and 26 
3% of the glomeruli at days 6 and 7, respectively. The per-
centage of glomeruli with FSGS lesions did not increase there-
after. However, at day 21, the lesions were more advanced,
showing a high degree of ECM accumulation, which had
culminated in the formation of segmental or even global scars
(Figure 1E).
EM analysis at days 1 and 3, using immersion fixed tissue,
showed global podocyte alterations with foot process effacement
and microvillous transformation. However, we did not observe
podocyte detachment or areas of denuded GBM. In contrast to
humans, mouse glomeruli frequently show prominent intraglo-
merular proximal tubular epithelial cells. These “glomerular prox-
imal tubular cells” and PEC showed extensive nuclear activation,
vacuolization, and widespread injury especially at day 1 (Figure
2A). As most FSGS lesions develop around days 6 and 7, we
performed extensive EM analysis at this time point, using both
immersion and perfusion fixed tissue. At days 6 and 7, in early
lesions, PEC appeared activated with enlarged nuclei and prom-
inent nucleoli. The number of PEC nuclei along Bowman’s cap-
sule appeared increased, and mitotic figures were occasionally
encountered (Figure 2, C and D). Detachment of PEC with naked
BC was occasionally observed (Figure 2B). In affected glomeru-
lar segments, the podocytes were markedly hypertrophic, showing
extensive vacuolization, resorption droplets, and formation of
pseudocysts (Figure 2D). In immersion-fixed tissue, Bowman’s
space was absent and hypertrophic podocytes were positioned
directly against PEC. In perfusion-fixed tissue, we frequently
observed cell bridges formed by a hypertrophic podocyte attached
to a PEC (in our hands perfusion fixation, as compared to immer-
sion, leads to more shrinkage of the glomerular tuft and flattening
of the PEC, resulting in a prominent Bowman’s space). At the
interface between hypertrophic podocytes and PEC, junctional
complexes were occasionally observed (Figure 2E). In immer-
sion-fixed tissue, we did occasionally see podocytes positioned
directly against denuded Bowman’s capsule (Figure 2B); in the
perfusion-fixed tissue, optically empty space was always present
and true attachment could not be confirmed. In more advanced
lesions, Bowman’s space was filled with an increased number of
epithelial cells (both fixation techniques), and pericellular accu-
mulation of matrix was observed (Figure 2F). Serial sections of
single glomeruli showed that FSGS lesions did not develop ex-
clusively close to the urinary pole but were also encountered near
the vascular pole (Figure 2C).
Podocyte Phenotype
To assess changes in podocyte phenotype during the develop-
ment of FSGS, we studied the expression of podocyte-specific
markers, WT-1, synaptopodin, ASD33 (an unidentified cell mem-
brane antigen, strongly expressed on mouse podocytes), the Thy-
1.1 antigen, Ki-67 as a marker of proliferation, desmin (associated
with podocyte dedifferentiation) (28), and CD68 (macrophage
marker). At day 3, in the absence of sclerotic lesions, we already
observed some decrease in the expression of ASD33 and synap-
topodin (data not shown). At days 6 and 7, changes were even
930 Journal of the American Society of Nephrology J Am Soc Nephrol 15: 928–939, 2004
more prominent (Figure 3A). The decrease of ASD33 and syn-
aptopodin expression was particularly observed in segments with
a tuft adhesion or tuft collapse. During the first 7 d, we did not
observe a change in the number of WT-1–positive cells. At day
21, we did observe a significant decrease in number of WT-1–
positive podocytes compared with days 1 and 6 (Table 2). At day
7, there was an increased expression of desmin in affected glo-
meruli. Desmin co-localized with the Thy-1,1 antigen and is
expressed by podocytes (Figure 3B). There was no glomerular
expression for CD68 (data not shown).
Figure 1. Histology of kidney
sections of Thy-1.1 trans-
genic (tg) mice at days 1, 3, 6,
7, and 21 after anti-Thy-1.1
mAb injection, (A-E, respec-
tively). (A) At day 1, light
microscopy revealed vacuol-
ization and detachment of
PEC (arrow). In proximal tu-
bules, many protein resorp-
tion droplets were observed
(*). (B) At day 3, a pro-
nounced hypertrophy of glo-
merular epithelial cells was
observed (*). (C and D) At
days 6 and 7, tuft adhesions
were observed (arrows). Glo-
meruli showed segmental col-
lapse of capillaries and an in-
creased number of epithelial
cells in Bowman’s space (*).
(E) At day 21, glomeruli
showed accumulation of
ECM in Bowman’s space,
with formation of segmental
scars (arrow); unaffected glo-
merulus (*). Methenamine
silver staining; original mag-
nification, 400. (F) Mild
hyalinosis (arrow) and a mi-
totic endocapillary cell (ar-
rowhead) were occasionally
observed. PAS staining; orig-
inal magnification, 400.
The percentage of glomeruli
with FSGS lesions at days 1,
3, 6, 7, and 21 is depicted in
panel G. * P 0.05, *** P
0.001 versus day 1.
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Characterization of the Proliferating Epithelial Cells
We have performed phenotypic analysis of proliferating epi-
thelial cells in Bowman’s space to clarify their origin. Sections
were stained for Ki-67. We observed an increase in the number of
proliferating cells, which peaked at day 3 for the interstitial
compartment and at day 7 for the glomerulus (approximately 5
baseline levels). Thereafter, the number of Ki-67–positive cells
declined to baseline levels (Figure 4A). Approximately 50% of
proliferating cells were located in Bowman’s space; the rest were
located within the glomerular tuft. Proliferating cells were often
located adjacent to adhesions (Figure 5B). In addition, proliferat-
ing cells were often positioned along Bowman’s capsule and
appeared to be PEC (Figure 4B). By double immunofluorescence,
we never observed co-localization of Ki-67 and the podocyte
specific Thy-1.1 antigen, arguing against the presence of prolif-
erating podocytes. We did not observe Thy-1.1 expression in
areas with accumulations of epithelial cells in Bowman’s space
(Figure 5A); however, in these areas, we did observe expression
of the neutral endopeptidase CD10 (Figure 5D), a protein that, in
glomeruli of control mice, is strongly expressed on PEC (Figure
5C).
Characterization of ECM
The composition of the ECM that is present in the adhesions
was studied by staining serial sections with antibodies directed
Figure 2. Electron microscopy. Injured glo-
meruli (days 1, 6, and 7) analyzed by trans-
mission electron microscopy (TEM). (A) At
day 1, PEC show widespread injury (insert).
Epithelia of Bowman’s capsule constituting
proximal tubular epithelial cells show exten-
sive vacuolization of the cytoplasm (*).
Podocytes showed foot process effacement
(arrow) and microvillous transformation (ar-
rowhead). (B) At days 6 and 7, segments of
denuded Bowman’s capsule were observed
(arrows). Podocytes positioned against the
denuded capsule were observed, thus form-
ing podocyte bridges between the GBM and
the bare Bowman’s capsule (*). (C-E) At
days 6 and 7, in early lesions, PEC appeared
activated with enlarged nuclei and prominent
nucleoli. The number of PEC nuclei along
Bowman’s capsule appeared increased ().
The hyperplasia of epithelial cells in Bow-
man’s space was also encountered near the
vascular pole (vp). Podocytes were markedly
hypertrophic showing extensive vacuoliza-
tion, resorption droplets (rd), and formation
of pseudocysts (*). In perfusion-fixed tissue,
cell bridges formed by a hypertrophic podo-
cyte attached to a PEC were observed (ar-
rows). At the site of attachment between hy-
pertrophic podocytes and PEC junctional
complexes were occasionally observed (ar-
rows in inserts 1 and 2). (F) Glomerular ep-
ithelial cells positioned in Bowman’s space
showed pericellular accumulation of ECM
(m). (A, B, and F: immersion-fixed; C-E:
perfusion-fixed) Original magnifications: A,
1500; insert, 3000; B, 7500; C, 600;
D, 500; E, 1000; insert 1, 12,000; in-
sert 2, 20 000; F, 4000.
Table 1. Number of nuclei in the urinary space in Thy-1.1
tg mice at days 1 and 7 after anti-Thy-1.1 mAb
injection and in saline injected micea
Group Number of Nuclei inBowman’s Space n
Saline 15.7 0.4 4
Day 1 14.7 0.6 3
Day 7 19.5 1.3b 4
a Significant increase in number of nuclei at day 7 after anti-
Thy-1.1 injection versus the saline injected mice and mice at day 1
after anti-Thy-1.1 injection.
b P  0.05 versus day 1 and saline.
932 Journal of the American Society of Nephrology J Am Soc Nephrol 15: 928–939, 2004
Figure 3. Podocyte pheno-
type. (A) Immunofluores-
cence for podocyte markers
(ASD33, synaptopodin, Thy-
1.1) and an anti-heparan sul-
fate single chain antibody
(HS4C3). Serial sections,
from control and anti-Thy-1.1
mAb–injected mice (day 7).
HS4C3 stains GBM and mes-
angium, showing normal tuft
architecture in the control and
a segmental lesion in Thy-
1.1–injected mice (day 7, *).
In control mice, ASD33, syn-
aptopodin, and Thy-1.1
showed a homogeneous stain-
ing pattern along the GBM.
There is a decrease in expres-
sion of ASD33 and synap-
topodin in areas with a seg-
mental lesion. There is still
high expression of the Thy-
1.1 antigen surrounding the
collapsed segment (arrow).
(B) IF for desmin and Thy-
1.1. Section from an anti-
Thy-1.1 mAb–injected mouse
(day 7). Thy-1.1 shows a nor-
mal podocyte staining in the
unaffected glomerulus (ar-
rowhead) but an irregular pat-
tern in an affected glomerulus
(*). The affected glomerulus
shows expression of desmin
(*). Desmin and Thy-1.1 co-
localize in the affected glo-
merulus (arrow). Original
magnification, 500.
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against the 2 and 4 chains of collagen IV. In addition, we
have used different anti-HS single chain antibodies that in
control mice predominantly stain Bowman’s capsule and not
the GBM. The ECM forming tuft adhesions stained for colla-
gen 2 (IV) and the anti-HS antibodies and were negative for
collagen 4 (IV) and HS4C3, an anti-HS antibody that stains
GBM and mesangium. Thus, the staining properties of the
newly formed ECM were identical to those of Bowman’s
capsule, arguing that this matrix was produced by PEC rather
than podocytes (Figure 6).
Discussion
Our study indicates that PEC play an important role in the
development of FSGS in the Thy-1.1 tg mouse. Although we
also observed distinct changes in the podocyte, we think that
the involvement of the PEC is more prominent. In the early
time points after induction of albuminuria, we observed PEC
injury, which was accompanied by denudation of segments of
the Bowman’s capsule. Thereafter, a cellular lesion consisting
of hypertrophic and hyperplastic glomerular epithelial cells
developed. Although hypertrophic podocytes contributed to
these lesions, most cells were proliferating PEC. Finally, the
cellular lesions turned into the adhesive scar that is the hall-
mark of FSGS. We have evaluated the composition of the scar
using antibodies against heparan sulfates and collagen (IV) 2
and 4, and the data indicated that the ECM that is present in
the scar is derived from the parietal epithelium.
Podocyte changes in our model consisted of podocyte hy-
pertrophy and podocyte foot process effacement. Of note, we
never observed detachment of the podocytes or areas of de-
nuded GBM. Our findings are in contrast with the observations
of Kriz et al., who have postulated a final common pathway for
the development of FSGS on the basis of their studies in
various rat models. Their proposed pathway toward FSGS
emphasizes the podocyte. Detailed histologic analyses have
pointed to the following sequence of events: (1) podocyte
injury; (2) detachment of podocytes and/or loss of podocytes
(podocytopenia) with denudation of the GBM; (3) adherence of
the naked GBM to PEC, which then lose intercellular contacts;
and (4) the formation of an adhesion between the glomerular
tuft and Bowman’s capsule, which allows “misdirected” filtra-
tion of plasma proteins to the periglomerular and peritubular
space, ultimately leading to global glomerulosclerosis and tu-
bulointerstitial fibrosis (13–17).
In our model, development of FSGS clearly follows other
pathways, thus suggesting that the model proposed by Kriz et
al. may not be applicable to FSGS in general. The latter
conclusion may not come as a surprise in view of the large
clinical variability of patients with FSGS. Thus far, most
studies have been done in rat models with evidence of glomer-
ular or systemic hypertension. Most notable is the observation
Figure 4. Cellular proliferation in the glomerulus and interstitial
compartment. (A) The number of Ki-67–positive proliferating cells in
the glomerulus gradually increased and peaked at day 7. Thereafter,
the number of Ki-67–positive cells declined to baseline levels. Peak
proliferation of cells within the interstitial compartment was observed
at day 3. (B) Immunohistochemistry for Ki-76. Immunoreactive nu-
clei stain brown. There is a high number of Ki-67–positive cells
positioned along Bowman’s capsule (arrow). We also observed Ki-67
positive cells (arrowhead) within the glomerular tuft. Original mag-
nification, 400; n  4; ** P  0.01 versus saline; *** P  0.001
versus saline.
Table 2. Number of WT-1–positive cells per mm2 in Thy-
1.1 tg mice at different days after anti-Thy-1.1
mAb injection and in saline injected micea
Group WT-1–Positive Cells/mm2 n
Saline 2388 69 4
Day 1 2518 169 5
Day 3 2497 122 4
Day 6 2728 81 4
Day 7 2332 247 4
Day 10 2137 412 3
Day 14 1974 72 4
Day 21 1694 141b,c 4
a In the first 7 d, there is no significant decrease in WT-1–
positive cells versus the saline-injected mice. There is a significant
decrease in number of WT-1–positive cells visible at day 21 versus
day 1 and 6.
b P  0.05 versus day 1.
c P  0.01 versus day 6.
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that in the reported studies there was always evidence of
capillary ballooning and glomerular hypertrophy. It is tempting
to speculate that the proposed pathway toward FSGS based on
the rat models is relevant for the process of secondary FSGS
that is observed in patients with reduced renal mass or long-
standing hypertension.
In our mouse model, we did not observe dilation of the
glomerular capillaries or glomerular hypertrophy. Rather, we
observed segmental collapse of the tuft with prominent extra-
capillary proliferation and frequent formation of adhesions.
Therefore, from a morphologic point of view, the lesions in our
mouse model closely resemble the collapsing variant of human
FSGS (2,27), although the segmental rather than global nature
of the process and the frequent formation of adhesions are
more typical for other variants of human FSGS. Collapsing
FSGS is a recently recognized entity, predominantly seen in
African Americans, also associated with HIV infection, and
with a poor prognosis and rapid progression toward end-stage
renal disease (ESRD). Collapsing FSGS in humans is associ-
ated with higher initial proteinuria and by some authors con-
sidered to be early and/or active lesions (29–33). To what
extent is our model representative of human collapsing FSGS?
Kriz et al. consider collapsing FSGS to be distinct from the
classical form, with a different underlying pathogenetic mech-
anism (14,15). It has been proposed that the cellular lesions
that are prominently present in collapsing FSGS consist of
podocytes that are dysregulated and are dedifferentiated with
loss of all podocyte-specific markers (34–37) and increased
expression of desmin (28). These podocytes are apparently no
longer growth restricted and have regained the ability to pro-
liferate. Normal podocytes are considered post-mitotic cells,
unable to proliferate due to high-level expression of cyclin-
dependent kinase inhibitors (CKI) p27 and p57 (34). In our
mouse model, we also observed podocyte hypertrophy and loss
of podocyte-specific markers, synaptopodin and ASD33, and
an increased expression of desmin, consistent with dedifferen-
Figure 5. Phenotype of proliferating cells. Panel A shows immunofluorescence in an anti-Thy-1.1 mAb–injected mouse (day 7), for Thy-1.1
(green) and HS4E4, an anti-heparan sulfate antibody (red). Nuclei are stained with TO-PRO-3 (blue staining). Shown is a FSGS lesion with
accumulation of cells in Bowman’s space (A, arrowhead). Thy-1.1 is present along the glomerular tuft, but there is no staining for Thy-1.1
within the lesion. HS4E4 stains Bowman’s capsule and tuft adhesions (A, arrow). Panel B shows immunofluorescence for collagen 2 (IV)
(red) and Ki-67 (green). Collagen 2 (IV) is present in Bowman’s capsule, mesangium, and tuft adhesions (B, arrow); Ki-67–positive cells are
located adjacent to tuft adhesions. Magnifications: A,500; B,600. Panels C and D show immunohistochemistry for CD10. Immunoreactive
cells stain brown. In control mice, CD10 is strongly expressed on PEC within the glomerulus (C). In a FSGS lesion (day 7), epithelial cells
in Bowman’s space strongly express CD10 (D). Original magnification, 400.
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tiation. However, because of the continued expression of podo-
cyte-specific markers, WT-1 and Thy-1.1, we were able to
show that podocytes in our model do not proliferate. Con-
versely, the orientation of the proliferating epithelial cells
relative to Bowman’s capsule and Bowman’s space, the strong
expression of CD10 and the composition of the ECM that is
produced by these cells strongly argue that the proliferating
cells are PEC. PEC have low-level expression of CKI and are
known to proliferate in response to different stimuli (38). A
typical example of PEC proliferation is seen in the formation of
crescents (39,40). Taken together, our data argue against a
dedifferentiated and dysregulated podocyte being responsible
for the formation of FSGS lesions in our model.
How should earlier data be interpreted? In the studies that
have assessed podocyte dedifferentiation, it is noteworthy that
these “dedifferentiated podocytes” had lost expression of
WT-1, GLEPP, synaptopodin, and podocalyxin. Some cells
had detached from the GBM, and these cells did not express
podocyte markers but rather demonstrated characteristic fea-
tures of macrophages (41,42). Thus, it cannot be excluded that
some of the cells present in cellular lesions in human collaps-
ing FSGS originate from proliferating PEC. Contribution of
Figure 6. Assessment of the compo-
sition of the ECM. Immunofluores-
cence for collagen IV 2 and 4
(green) and HS4E4 (red) in serial
sections of a glomerulus with adhe-
sions (day 7). (A) Within the glo-
merulus, collagen 4 (IV) is ex-
pressed specifically in the GBM. (B)
Collagen 2 (IV) is expressed in
Bowman’s capsule, mesangium, and
the tuft adhesions. (C and D) HS4E4
stains Bowman’s capsule and the ac-
cumulations of ECM, which form
the tuft adhesions (arrows). (E)
There was no co-localization of col-
lagen 4 (IV) and heparan sulfate
identified by HS4E4. (F) Collagen
2 (IV) shows co-localization with
the HS4E4 heparan sulfate in Bow-
man’s capsule and the tuft adhe-
sions. Original magnification, 500.
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PEC to cellular lesions in human collapsing FSGS has been
previously proposed by other authors on the basis of positive
staining for cytokeratin (38). We also need to consider the
possibility that FSGS lesions may develop differently in mouse
as compared with humans. In mouse glomeruli, proximal tu-
bular epithelial cells are present within the glomerulus close to
the urinary pole. It cannot be excluded that proximal tubular
epithelial cells proliferate and influence FSGS development.
The fact that in our mice FSGS lesions develop not only close
to the urinary pole but also in the perihilar region argues
against this possibility. Nevertheless, the existence of proximal
tubular epithelial cells within Bowman’s capsule in mice com-
plicates any analysis of glomerular cell changes.
The finding that cellular lesions in our model are of PEC
origin does not preclude an important role for the podocyte in
the development of FSGS lesions. The initial bridge consists of
a hypertrophic podocyte that attaches to PEC or comes into
contact with Bowman’s capsule. Attachment of a hypertrophic
podocyte to PEC or appositioning to denuded Bowman’s cap-
sule may be the critical event that leads to an FSGS lesion. In
this respect, our findings partly resemble crescent formation in
a mouse model of crescentic glomerulonephritis (39). These
authors observed that podocyte bridges between the capillary
tuft and Bowman’s capsule precede the development of cres-
cents. In this model, PEC injury with gaps between the PEC
and areas of denuded Bowman’s capsule was not observed.
The authors suggest that the bridging podocyte is critically
involved in regulating proliferation of PEC. In our model, a
similar effect may then be responsible for the proliferation of
the PEC that we observed. Le Hir et al. (39) suggests that the
podocyte produced basement membrane-like material that
formed in continuity with the Bowman’s capsule. However,
this conclusion was based on staining for collagen IV with a
polyclonal antibody, which does not allow differentiation be-
tween different -chains. Our findings clearly prove that the
adhesion is made up of Bowman’s capsule like material. In
Figure 7, we have proposed a scheme for the sequence of
events that ultimately lead to FSGS in our model.
How to reconcile both models with human data? As men-
tioned above, the classical pathway of FSGS as described by
Kriz et al. in rat models of hypertrophy and hypertension may
best fit with secondary FSGS. Our model may bear more
resemblance to primary FSGS. This needs to be further inves-
tigated using human renal biopsy material. Notably, PEC dam-
age in biopsies from patients with FSGS is frequently observed
(43–45) and possibly caused by protein overload.
Figure 7. Hypothetical sequence of events leading to cellular FSGS lesions in the Thy1.1 tg mice, illustrated in schematic drawings. (A) Days
1–7. Injury of the glomerular epithelial cells. Podocytes (green) show foot process effacement and microvillous transformation (not illustrated).
There is no podocyte detachment. PEC (blue) show vacuolization and detachment, leading to “bare” segments of Bowman’s capsule
(Bowman’s capsule is drawn as a gray line). (B) Days 3–7. Podocytes become hypertrophic (with activated nuclei, resorption droplets, and
pseudocysts) and form bridges between the glomerular tuft and Bowman’s capsule. (C) Days 6 and 7. Proliferation of PEC adjacent to the
bridging podocytes, filling up Bowman’s space, giving the appearance of a cellular FSGS lesion. (D) The proliferating PEC in Bowman’s space
produce ECM (gray) that eventually forms tuft adhesions.
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In conclusion, PEC play an important role in the formation
of cellular FSGS lesions in the Thy-1.1 tg mouse.
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